BBIO · BridgeBio Pharma, Inc.

$79.86 -1.35 (-1.66%) At close · Aug 14

Market Cap

$15.61B

195.49M

Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.

Fiscal 2025

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Neil Kumar	Chief Executive Officer	$1,044,000	$1,404,000	$10,606,275	$1,874,992	—	$15,318	$14,944,585
Thomas Trimarchi	President and Chief Financial Officer	$675,589	$525,000	$4,602,488	—	—	$29,293	$5,832,369
Brian Stephenson	Ph.D., CFA Former Chief Financial Officer	$156,431	—	—	—	—	$528,230	$684,661

Fiscal 2024

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Neil Kumar	Chief Executive Officer	$987,539	$1,038,800	$12,541,433	$999,991	—	$14,160	$15,581,923
Thomas Trimarchi	President and Chief Financial Officer	$643,654	$454,200	$5,316,062	$60,584	—	$27,558	$6,502,058
Brian Stephenson	Ph.D., CFA Former Chief Financial Officer	$661,046	$328,000	$4,318,393	$342,088	—	$14,160	$5,663,687

Fiscal 2023

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Neil Kumar	Chief Executive Officer	$742,000	$779,100	$6,123,793	$4,499,993	—	$13,740	$12,158,626
Brian Stephenson	Ph.D., CFA Former Chief Financial Officer	$650,000	$487,500	$3,170,759	$2,329,997	—	$13,740	$6,651,996

Fiscal 2022

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Neil Kumar	Chief Executive Officer	$1,106,000	$940,100	$4,571,519	—	—	$56,818	$6,674,437
Brian Stephenson	Ph.D., CFA Former Chief Financial Officer	$650,000	$487,500	$1,807,692	—	—	$12,200	$2,957,392

Fiscal 2021

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Neil Kumar	Chief Executive Officer	$725,000	—	$2,638,134	$22,230,967	—	$32,858	$25,626,959
Brian Stephenson	Ph.D., CFA Chief Financial Officer	$600,000	$225,000	$1,442,224	$6,398,473	—	$11,600	$8,677,297

Fiscal 2020

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Neil Kumar	Chief Executive Officer	$550,000	$825,000	$2,368,511	$6,299,998	—	$11,400	$10,054,909
Michael Henderson	Chief Business Officer	$515,000	$300,000	$7,072,500	$91,899	—	$11,843	$7,991,241
Brian Stolz	Chief Operating Officer	$511,362	$25,000	$736,854	$1,992,182	—	$1,975,453	$5,240,851
Cameron Turtle	Ph.D.\ Chief Strategy Officer	$400,000	$210,000	$3,940,081	—	—	$11,400	$4,561,482
Brian Stephenson	Ph.D., CFA Chief Financial Officer	$550,000	$712,500	$789,494	$2,099,996	—	$11,943	$4,163,933
Charles Homcy	Chairman of Pharmaceuticals	$500,000	$100,000	—	$1,199,992	—	$55,812	$1,855,805

Fiscal 2019

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Neil Kumar	Chief Executive Officer	$502,765	$360,000	$13,863,445	$11,573,049	—	$34,804	$26,334,063
Brian Stolz	Chief Operating Officer	$146,780	$93,750	$6,860,780	$1,045,003	—	—	$8,146,313
Charles Homcy	Chairman of Pharmaceuticals	$513,808	—	$2,111,579	$3,128,716	—	$221,737	$5,975,842
Brian Stephenson	Ph.D., CFA Chief Financial Officer	$420,000	$189,000	$132,600	$3,430,781	—	$26,586	$4,198,967

Fiscal 2018

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Brian Stephenson	Ph.D., CFA Chief Financial Officer	$74,375	$330,240	$1,942,500	—	—	—	$2,347,115
Neil Kumar	Chief Executive Officer	$450,000	—	—	—	—	—	$450,000

Executive changes

Person	Role	Change	Effective	Filed
Hannah A. Valantine	Class I director	Appointed	2026-06-22	2026-06-26
Frank P. McCormick	Class I director	Appointed	2026-06-22	2026-06-26
James C. Momtazee	Class I director	Appointed	2026-06-22	2026-06-26
Randal W. Scott	member of the Board of Directors	Resigned	2026-06-22	2026-06-26
Brian C. Stephenson	Chief Financial Officer	Terminated	2025-03-17	2025-03-17
Thomas Trimarchi	President and Chief Operating Officer	Appointed	2024-07-23	2024-07-23
Brenton L. Saunders	member of the Board of Directors	Resigned	2023-03-06	2023-02-23
Frank McCormick, Ph.D., F.R.S., D.Sc. (Hon)	director of the Company	Appointed	2023-02-21	2023-02-23
Richard H. Scheller, Ph.D.	member of the Board of Directors	Resigned	2023-02-21	2023-02-23

Key facts CIK 1743881 CUSIP 10806X102 13F (30d) 434 filings 429 filers Visit website Investor relations